[Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment

<div>B cell pseudotime trajectories and DEGs of subpopulations of patient 1. (a) The colors of B cells lineage development darkened with the pseudotime developing. (b) The colors of B cells lineage development darkened with the WBC increasing.(c) The B cell pseudotime trajectories were distinguished to 3 stages of CLL. (d) The B cell pseudotime trajectories of each stage of CLL. (e) The UMAPs showed the distribution of B cell subpopulation of each stage in CLL. (f) The violin plots present little expressed difference of different B cell markers in the 3 stages.</div>

Computational and Mathematical Methods in Medicine

fig7

Figure 7

Figure 7: [Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment 

Figure 7 | [Retracted] Analysis of Data on Fludarabine, Cyclophosphamide, and Rituximab Chemoimmunotherapy for Chronic Lymphocytic Leukemia Shows High Patient Heterogeneity and the Need for More Consideration of Individualized Treatment 